Kornimate/medical-research-clean huggingface dataset:
effectiveness of a novel warm-up in decreasing risk factors for acl injury in female youth soccer players

Conditions: ACL Injury

Summary: there is a large number of young women who sustain serious knee injuries from playing soccer. female athletes are at high risk of knee injuries from soccer than males. we will conduct a research project to assess the effect of a warm-up on changing some of the movement patterns thought to contribute to these serious knee injuries. it is hypothesized that a core position and control movement strategy (core-pac) group reduce biomechanical risk factors at the knee compared to a control after the training program.

there is a large number of young women who sustain serious knee injuries from playing soccer. female athletes are at high risk of knee injuries from soccer than males. we will conduct a research project to assess the effect of a warm-up on changing some of the movement patterns thought to contribute to these serious knee injuries. a core position and control movement strategy (core-pac) may be one method of modifying high-risk movements such as side-cutting. the core-pac is a simple method of getting the centre of mass (com) closer to the plant foot or base of support (bos). moving the com closer to the bos may bias joint loading to the sagittal rather than the frontal and transverse planes, which often occurs in female athletes and poses a risk for acl injury. in this study, we will conduct a randomized controlled trial to compare a core-pac trained group to a control group for peak flexion angles and peak abduction moments at the knee during a side-cut and an unanticipated side-cut prior to kicking a soccer ball and a side-hop task after a six-week training program. it is hypothesized that a core-pac group would have greater peak flexion angles and lower peak abduction moments at the knee compared to a control after the training program.

Eligibility criteria:
inclusion criteria: * 14-17 years of age; * have no injuries for six weeks prior to testing; * have no medical problems preventing them from participating in the study. exclusion criteria: * have a previous acl injury or repair; * have a back or lower limb injury that kept them from playing or training for greater than 30 days in the past year; * presently using a supplemental exercise based program; * have any medical or neurologic condition that would impair their ability to perform the tasks.

Keywords: acl, knee , injury,
24-hour study of dorzolamide/timolol and latanoprost/timolol fixed combinations

Conditions: Open-angle Glaucoma

Summary: the primary objective of this crossover trial is to compare the 3-month mean 24-hour intraocular pressure (iop) control and safety of dorzolamide/timolol fixed combination (dtfc) given twice daily, versus latanoprost/timolol fixed combination (ltfc) given in the evening and placebo given in the morning, versus adjunctive therapy with dtfc given twice daily and latanoprost 0.005% given once in the evening in open-angle glaucoma patients who are insufficiently controlled with latanoprost monotherapy.


Eligibility criteria:
inclusion criteria: * consecutive primary open-angle (poag) and exfoliative glaucoma (xfg) patients will be recruited. * patients included will be older than 29 years * have early to moderate poag, or xfg (less than 12 mean deviation visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio) * will be on therapy with latanoprost for more than 3 months; * have at treated baseline iop at 10:00 (two consecutive readings) greater than 21 mm hg * have a reliable visual field (at least two visual fields with less than 30% fixation losses, false positives or negatives) * have a best corrected distance snellen visual acuity \> 1/10 * have corneal pachymetry within the 550 ± 55 μm range, understand the study instructions and are willing to attend all follow-up appointments * are willing to comply with study medication usage * and have open, normal appearing angles exclusion criteria: * patients will be excluded if they have: a risk for significant deterioration during the study * known previous history of lack of adequate response (\< 10% reduction) to any topical glaucoma medication * less than 20% daytime iop reduction on latanoprost; * systemic contraindications to topical beta-blockers (asthma, bradycardia, severe congestive heart disease) * known contraindications to prostaglandins, history of ocular herpetic disease, or cystoid macular edema * history of trauma, inflammation, surgery or past use of steroids (within two months) * severe dry eyes * use of contact lenses * signs of ocular infection, except blepharitis * corneal abnormality that may affect iop measurements * unwillingness to accept the risk for hyperchromia of the iris or development of hypertrichosis * and females of childbearing potential or lactating mothers
nd-yag laser iris depigmentation for cosmoses

Conditions: Iris Depigmentation

Summary: nd-yag laser for changing iris coloration by the principle of depigmentation for cosmoses is that procedure safe or not a prospective study

nd-yag laser for changing iris coloration by the principle of depigmentation for cosmoses is that procedure safe or not a prospective study safety will be assessed by measuring iop using goldman applanation tonometry pre and post-session. visual acuity assessment in log-mar pre and post-session. refraction assessment pre and post-session. lens and fundus assessments on slit-lamp and using auxiliary lens 78d

Eligibility criteria:
inclusion criteria: * clear cornea * clear lens * normal iop \< 20 mmhg * adults aged more than 18 years old * normal fundus * dark pigmented iris (black or brown) exclusion criteria: * glaucomatous patients and those receiving anti-glaucoma treatment. * corneal or lens opacity. * any fundus abnormality

Keywords: nd-yag laser iris cosmoses
effectiveness and safety of nailner brush 2in1 in onychomycosis

Conditions: Onychomycosis

Summary: evaluate the effectiveness of nailner brush 2-in-1 in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface after 6 months of treatment compared to baseline.


Eligibility criteria:
inclusion criteria: * patient having given freely her/his informed, written consent. * patient having a good general health. * age: between 18 and 70 years. * patient with superficial onychomycosis or light to moderate distolateral onychomycosis (without matrix involvement and involvement from 10 to 60%) on at least one great toenail. * patient with positive koh staining. * patient cooperative and aware of the device modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected. * patient being psychologically able to understand information and to give their/his/her consent. * patient who agrees to refrain from receiving pedicure, artificial nails and/or cosmetic nail varnish or other medication on the nail being treated for the entire study duration. * female of childbearing potential should use a contraceptive regimen recognized as effective since at least 4 weeks before screening visit and during all the study. exclusion criteria: * pregnant, breastfeeding woman or woman planning a pregnancy during the study; * patient enrolled in another clinical trial or which exclusion period is not over. * patient having used any systemic antifungal treatment in the last 6 months before screening and/or any topical antifungal treatment in the last months before screening visit. * patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk; * patient suffering from a severe or progressive disease (at investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, poor blood circulation hiv, psoriasis, lichen planus, immunosuppressive pathology, moderate and high risk obesity (bmi ≥30); * patient having a known allergy or hypersensitivity to one of the constituents of the investigational device. * patient with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis...).
registry of major liver resections including alpps and other liver resections in two stages

Conditions: Liver Neoplasms; Liver Regeneration

Summary: recently a new method of induce similar hypertrophy in the liver as is observed after hepatectomy has been described and was given the eponym "allps". "alpps" stands for associating liver partition with portal vein ligation for staged hepatectomy (alpps). since the procedure is used worldwide this international registry was created to enable tracking of cases performed worldwide for safety and outcomes and innovations by the groups involved as well as allows a non-randomized comparison to the conventional methods of portal vein occlusion.

the alpps registry is accessible online through the data portal www.allps.net. registered members recieve access through a member id and password. data submission is supported by the secutrial software, supported by the clinical trials center of the university of zurich. all data submitted are anonymized before entry through the secutrial software. administration of the registry data is performed through the department of visceral and transplantation surgery in the university hospital zurich and the clinical trials center of the university of zurich, switzerland, in collaboration with the italian hospital in buenoas aires, argentina. a scientific committee has been appointed to give approval for any data analysis. any participating center may apply for data analysis. particiating international centers have responsibility for the validity of the data submitted and the respective local institutional review procedures.

Eligibility criteria:
inclusion criteria: * all patients who undergo the new alpps procedure * patients undergoing any other modification of alpps like portal vein embolization (pve) or banding of the liver with portal vein ligation or embolisation or other liver resection in two stages resembling alpps_ * male and female patients 18 years to no limit * prior registering the data, patient was informed and did not object to the use of his/her anonymized medical data in this registry exclusion criteria: * no exclusion criteria apply for a registry

Keywords: liver neoplasms liver regeneration
effects of doxazosin gastrointestinal therapeutic system on ambulatory blood pressure and cardiovascular risk factors in uncontrolled hypertensive patients

Conditions: Hypertension

Summary: the primary objective was to determine the effects of the gastrointestinal therapeutic system (gits) formulation of doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by 24-hour diastolic blood pressure.


Eligibility criteria:
inclusion criteria: * eligible subjects were males or females ≥18 years of age with a diagnosis of primary essential hypertension and currently taking 1 or 2 individual antihypertensive agents * dosing for entry antihypertensive medication was at the accepted efficacious dose or the maximum tolerated dose and had to be stable for at least 4 weeks prior to study entry * subjects were required to have clinic sitting dbp ≥95 and ≤110 mmhg and sbp ≥140 and ≤180 mmhg as an average of 3 readings on their current antihypertensive therapy at visits 1 and 2 exclusion criteria: exclusion criteria included, but were not limited to: * subjects taking antihypertensive medications for other indications (i.e. arrhythrma, unstable angina, chf, etc.) * orthostatic hypotension, defined as a decrease of at least 20 mmhg systolic or 1ommhg diastolic pressure between sitting and standing blood pressures after 2 rmnutes, or known fluid depletion.

Keywords: essential hypertension, doxazosin, ambulatory blood pressure monitoring
a study to compare the immune response and safety elicited by henogen's adjuvanted hepatitis b vaccine compared to gsk biologicals adjuvanted hepatitis b vaccine in pre-dialysis and dialysis patients who have not been exposed to hepatitis b.

Conditions: Hepatitis B

Summary: the pre-dialysis, peritoneal dialysis and haemodialysis patients would benefit from an improved hepatitis b vaccine, which will elicit stronger and faster cellular and humoral immune responses after the primary vaccination course.

study participants will receive either henogen's adjuvanted hepatitis b vaccine or gsk biologicals' adjuvanted hepatitis b vaccine. the study involves a total of 7 visits and blood samples will taken at each of these visits.

Eligibility criteria:
inclusion criteria: * a male or female subject 15 years of age or older at the time of the study entry. * written informed consent obtained from the subject/ from the parent or guardian of the subject. * seronegative for anti-hbs antibodies, anti-hbc antibodies and for hbsag at screening. * pre-dialysis patients, peritoneal dialysis patients or haemodialysis patients. * non-childbearing potential female exclusion criteria: * use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * use of any registered vaccine within 7 days before the first dose of study vaccine. * previous vaccination against hepatitis b (whether or not the subject responded to the vaccine). * history of hepatitis b infection. * known exposure to hepatitis b virus within 6 months. * use of immunoglobulins within six months preceding the first study vaccination. * immunosuppression caused by the administration of parenteral steroids or chemotherapy (oral steroids are allowed). * any confirmed or suspected human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * acute disease at the time of enrolment. acute disease is defined as the presence of a moderate or severe illness with or without fever. all vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral/ axillary temperature \< 37.5°c (or 37 °c in czech republic). * oral/axillary temperature superior or equal to 37.5°c (or 37 °c in czech republic). * pregnant or lactating female

Keywords: dialysis pre-dialysis hepatitis b vaccine prophylaxis
pronto for patient blood management

Conditions: Anemia

Summary: the concept of patient blood management requires preoperative diagnostic of anemia. to avoid the harmful procedure of venous puncture for drawing a blood sample, noninvasive measurement of hemoglobin has been developed. however noninvasive measurement of hemoglobin has yet been not accurate enough to replace invasive hemoglobin measurement. this study investigates if a noninvasive measurement tool can serve as a screening tool to find out for which patients invasive measurement of hemoglobin is necessary.

the noninvasive hemoglobin measurement tool pronto® can measure hemoglobin noninvasively by a sensor clip. the investigators analyzed previous studies with the pronto device and calculated two cut-off values of the noninvasive hemoglobin device. if noninvasive hemoglobin values are higher than cut off value 1 the investigators postulate that with a sensitivity of 99% the participant has no anemia. to confirm this, participants who are supposed to undergo elective surgery and come to the preoperative anesthetic ambulance are measured by the pronto-device. the noninvasive measurements are compared with the laboratory values of the patients and cut-off value 1 can be confirmed.

Eligibility criteria:
inclusion criteria: * adults and children \>=3kg that are planned to undergo elective surgery * written informed consent exclusion criteria: * no written informed consent
social-environmental, psychosocial, behavioral, clinical and biological drivers of disparities in liver disease progression among korean american with chronic hepatitis b infection

Conditions: Chronic Viral Hepatitis; Hepatitis B Infection

Summary: this study explores how psychosocial factors (e.g., chronic stress, depression) may lead to liver disease progression such as liver cirrhosis or liver cancer among korean american chronic hepatitis b infection patients. gathering health information over time from korean americans with chronic hepatitis b infection may help doctors find better methods of treatment and on-going care.

primary objectives: i. to estimate the prevalence of chronic hepatitis b (chb) phenotype and liver disease severity at enrollment visit, and model how multiple social-environmental, psychosocial, behavioral, clinical and biological attributes are associated with variation in chb phenotype and disease severity. ii. to identify how these same attributes are associated with disease progression over time. secondary objective: i. to examine the moderating effects of these multi-level factors on the relationship between liver disease progression and adverse liver disease outcome (e.g., hepatocellular carcinoma \[hcc\]), as well as mediating effects of liver disease progression on the relationship between psychosocial factors and liver cancer or death. exploratory objective: i. using an explanatory mixed methods approach, to understand the care-seeking behaviors, and dynamics of care, within an ethnically concordant liver disease care model, and how these factors may have both direct and mediational effects on adherence, treatment effectiveness, and adverse disease outcomes. outline: patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. patients' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * willing to comply with all study procedures and be available for the duration of the study * korean-american male or female, age over 18 and older * chb patients who have lab and medical record data (including hepatitis b virus \[hbv\] deoxyribonucleic acid \[dna\] viral load, hepatitis b virus e antigen \[hbeag\] status, and liver enzyme values) exist from 2015 or before exclusion criteria: * patients who have received a diagnosis of hcc, although they may have been diagnosed with cirrhosis * patients who have been diagnosed with other viral infections (hepatitis c virus \[hcv\], human immunodeficiency virus \[hiv\], etc.) * patients who have total baldness
evaluation of commercial sars-cov-2 antibody immunoassays for covid-19

Conditions: Covid19

Summary: achieved serum samples of persons with or without evidence of covid-19 infection are tested using the different commercial sars-cov-2 antibody immunoassays. the performance of the immunoassays is then assessed by comparing the 2 groups of samples.

achieved serum samples of the different testing groups are retrieved and tested with the immunoassays according to manufacturer's instruction. the test results are then compared and analyzed with statistical tests to assess the immunoassays'performance

Eligibility criteria:
inclusion criteria for covid-19 infected sera: any patient with pcr confirmed covid-19 infection inclusion criteria for covid-19 negative sera: sera collected after a negative sars-cov-2 pcr exclusion criteria: -
an in-hospital family member cardiopulmonary resuscitation (cpr) education program

Conditions: Cardiac Arrest; Coronary Disease; Cardiovascular Risk Factors

Summary: each year in the united states, 300,000 people suffer from a cardiac arrest (ca), and of them, there is a 90% mortality rate. out-of-hospital arrests, in particular, have a 1-5% survival to hospital discharge. high quality cpr is crucial to lowering the mortality rate and increasing survival, yet only 15-30% of out-of-hospital ca victims receive bystander cpr. studies have shown that prompt administration of cpr dramatically improves outcomes. in a recent study from switzerland, lay bystander cpr doubled the survival rate at one month. our study will look to train family members of at-risk cardiac patients in the skills of cpr through the american heart association's (aha) cpr anytime friends and family personal learning program (cpr anytime) to see if these family members are able to learn and perform quality cpr in the event that their family member should suffer a cardiac arrest.

using the aha's cpr anytime kit, we will work with family members of patients at high risk for a ca to learn lifesaving cpr skills. we will modify the aha cpr video using the new aha recommendations for bystanders which suggests doing chest compression only cpr. using the original aha video and our modified chest compression only video, we will randomize family members of patients at high risk for ca to one of these groups. our research assistants will also be blinded to which video these subjects will be watching. after watching the video, we will have the subjects perform cpr on a mannequin using a cpr recording device that records chest compression rate and depth. we will follow up with the family members at 3 months, 6 months and 12 months to see if they retained their cpr knowledge and skills and to see if they had been in a situation where their cpr skills were needed and assess whether they performed their skills or not. we will also measure the number of people with whom the subjects shared their cpr anytime kits-a quantity known as the multiplier effect to determine if they had shared the cpr anytime kit with their family and friends, thereby increasing the possible number of lay persons trained in cpr and in turn able to perform bystander cpr if needed.

Eligibility criteria:
inclusion criteria: * family member's of patients with known coronary disease or cardiovascular risk factors, such as history of diabetes and hypertension. exclusion criteria: * if someone is physically unable to undergo cpr training * someone who has received cpr training in the past 2 years
comparasion of the immediate effect of myofascial relaxation technique and kinesiology taping

Conditions: Diabetes Mellitus; Plantar Fascia

Summary: as a result of glycation of collagen fibers in diabetes mellitus, an increase in thickness and stiffness is observed in the plantar fascia, which is a connective tissue. these changes in the plantar fascia affect the windlass mechanism of the foot, normal range of motion and foot plantar pressure distribution. these biomechanical effects may cause the development of diabetic foot ulcers in the later stages of the disease. we hypothesis that myofascial release technique and kinesiology taping methods have an effect on plantar fascia stiffness and plantar pressure distribution in diabetic patients. the aim of this study is to investigate the immediate effects of the two methods on the stiffness of the plantar fascia and foot sole pressure distribution in diabetic patients.


Eligibility criteria:
inclusion criteria: * those with diabetic foot ulcer development risk groups 1 and 2 according to the international working group on the diabetic foot (iwgdf) * those who have diabetes for at least 5 years * ambulation independently without using an assistive device exclusion criteria: * those with foot posture deformity * having another disease that will affect connective tissue properties * presence of orthopedic or neurological disorders that will affect plantar load distribution * history of surgery and fractures from the ankle-foot in the last 6 months

Keywords: stiffness creep plantar fascia diabetes mellitus